Customer Focus on Major Pharmaceutical Companies
First written in FY2016. 8 of 18 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-10-09.
The whole theme swung hardest in 2020: 1 of 8 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2026RaisedAnnual report
「To address these risks, we are working to expand our customer base by developing new customers and capturing demand not only from pharmaceutical companies and emerging biopharmaceutical companies, but also from medical device and software (SaMD) developers, through the expansion of our global business and operations such as drug discovery support services in response to changing customer needs.」
The company has explicitly identified medical device and software (SaMD) developers, in addition to pharmaceutical and emerging biopharmaceutical companies, as targets for new customer development and is expanding its customer base. - FY2026-H1AdvancedAnnual report
「The company has recently received multiple large projects in Japan from pharmaceutical companies in Japan and overseas, and orders are recovering. Revenue increased year on year, while the operating loss also narrowed. Although drug loss has become a serious social issue in Japan and the difficult market environment continues, the company is securing orders by continuing domestic and international sales activities in cooperation with its European, U.S., and Asian businesses.」
It was stated that the company had received multiple large projects in Japan from pharmaceutical companies in Japan and overseas and was securing orders through sales activities in cooperation with its European, U.S., and Asian businesses. - FY2025-H1AdvancedAnnual report
「The Japanese pharmaceutical industry remains in a difficult market environment as structural reforms, including successive calls for early retirement at pharmaceutical companies, continue. Nevertheless, we are steadily continuing sales activities, in cooperation with our European, U.S., and Asian businesses, such as proposing that overseas biotech companies enter the Japanese market.」
In addition to developing customers centered on major Japanese pharmaceutical companies, the company continues sales activities in cooperation with its European, U.S., and Asian businesses to propose that overseas biotech companies enter the Japanese market. - FY2024RaisedAnnual report
「We have historically expanded our business by obtaining repeat orders from major Japanese pharmaceutical companies, but orders from pharmaceutical companies in Europe and the United States are also increasing as our bases in each region cooperate to strengthen global information gathering and sales activities. In addition, by focusing on European and U.S. biotech start-ups with promising development pipelines and making detailed proposals tailored to their needs, we will differentiate ourselves from major global CROs and expand our customer base.」
The policy of expanding the target customer base from major Japanese pharmaceutical companies to pharmaceutical companies and biotech start-ups in Europe and the United States has taken concrete shape. - FY2024-Q3RestatedAnnual report
「In Asia, we are strengthening sales cooperation with Japan and the United States and focusing on developing orders from local pharmaceutical companies. We have also been approached by multiple new customers regarding potential projects.」
The company continues to strengthen sales cooperation with Japan and the United States, develop orders from local pharmaceutical companies in Asia, and receive inquiries about potential projects from multiple new customers. There has been no substantive change in the description since the previous quarter. - FY2024-Q2AdvancedAnnual report
「In Asia, we are strengthening sales cooperation with Japan and the United States and focusing on developing orders from local pharmaceutical companies. We have also been approached by multiple new customers regarding potential projects.」
As a result of strengthening sales cooperation with Japan and the United States and developing orders from local pharmaceutical companies in Asia, the company has been approached by multiple new customers regarding potential projects. - FY2024-Q1Progress in inquiries from Japanese pharmaceutical companies and acquisition of new projectsAnnual report
「Inquiries from Japanese pharmaceutical companies have been trending upward, and new projects are currently being acquired, providing an outlook for a recovery from the second quarter onward.」
It was stated that inquiries from Japanese pharmaceutical companies were trending upward, new projects were being acquired, and a recovery was expected from the second quarter onward. - FY2021Lower combined reliance on the 3 major customersAnnual report
「CHUGAI PHARMACEUTICAL CO.,LTD. 1,521,281 14.8 エーザイ株式会社 1,488,231 14.5 小野薬品工業株式会社 727,047 7.1」
Revenue reliance on the 3 major customers totaled 36.4%, down from 41.4% in the previous fiscal year. The shares of CHUGAI PHARMACEUTICAL CO.,LTD. and エーザイ株式会社 increased, while that of 小野薬品工業株式会社 declined to 7.1%. - FY2020RestatedAnnual report
「We believe that focusing our customer base on a limited number of major pharmaceutical companies can avoid errors and mistakes arising from the existence of numerous methods and procedures, thereby improving clinical trial quality and enhancing competitiveness.」
The policy of linking a focus on a limited number of major pharmaceutical companies to improvements in clinical trial quality and competitiveness continues. - FY2018RestatedAnnual report
「We believe that focusing our customer base on a limited number of major pharmaceutical companies can avoid errors and mistakes arising from the existence of numerous methods and procedures, thereby improving clinical trial quality and enhancing competitiveness.」
The policy of linking a focus on a limited number of major pharmaceutical companies to improvements in clinical trial quality and competitiveness continues. - FY2017RestatedAnnual report
「We believe that focusing our customer base on a limited number of major pharmaceutical companies can avoid errors and mistakes arising from the existence of numerous methods and procedures, thereby improving clinical trial quality and enhancing competitiveness.」
The policy of focusing on major pharmaceutical companies to improve familiarity with procedures, clinical trial quality, and competitiveness continues. - FY2016First statedAnnual report
「We believe that focusing our customer base on a limited number of major pharmaceutical companies can avoid errors and mistakes arising from the existence of numerous methods and procedures, thereby improving clinical trial quality and enhancing competitiveness.」
The company explains its policy of linking a limited customer base to familiarity with clinical trial procedures and improvements in quality and competitiveness.